Ethical and legal issues in psychedelic harm reduction and integration therapy

Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity...

Full description

Saved in:
Bibliographic Details
Published inHarm reduction journal Vol. 18; no. 1; pp. 40 - 14
Main Authors Pilecki, Brian, Luoma, Jason B., Bathje, Geoff J., Rhea, Joseph, Narloch, Vilmarie Fraguada
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 07.04.2021
BioMed Central
BMC
Subjects
Online AccessGet full text
ISSN1477-7517
1477-7517
DOI10.1186/s12954-021-00489-1

Cover

Loading…
Abstract Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status and many therapists are unsure of how they might practice in this area. This paper explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients' use of psychedelics. It is argued that therapists can meet with clients before and after their own personal psychedelic experiences in order to help clients minimize risk and maximize benefit. Common clinical scenarios in this growing clinical area will also be discussed.
AbstractList Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status and many therapists are unsure of how they might practice in this area. This paper explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients' use of psychedelics. It is argued that therapists can meet with clients before and after their own personal psychedelic experiences in order to help clients minimize risk and maximize benefit. Common clinical scenarios in this growing clinical area will also be discussed.
Abstract Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status and many therapists are unsure of how they might practice in this area. This paper explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients' use of psychedelics. It is argued that therapists can meet with clients before and after their own personal psychedelic experiences in order to help clients minimize risk and maximize benefit. Common clinical scenarios in this growing clinical area will also be discussed.
Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status and many therapists are unsure of how they might practice in this area. This paper explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients' use of psychedelics. It is argued that therapists can meet with clients before and after their own personal psychedelic experiences in order to help clients minimize risk and maximize benefit. Common clinical scenarios in this growing clinical area will also be discussed.Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status and many therapists are unsure of how they might practice in this area. This paper explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients' use of psychedelics. It is argued that therapists can meet with clients before and after their own personal psychedelic experiences in order to help clients minimize risk and maximize benefit. Common clinical scenarios in this growing clinical area will also be discussed.
Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status and many therapists are unsure of how they might practice in this area. This paper explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients' use of psychedelics. It is argued that therapists can meet with clients before and after their own personal psychedelic experiences in order to help clients minimize risk and maximize benefit. Common clinical scenarios in this growing clinical area will also be discussed. Keywords: Psychedelics, Psychedelic-assisted therapy, Psychedelic integration, Harm reduction
ArticleNumber 40
Audience Academic
Author Bathje, Geoff J.
Pilecki, Brian
Narloch, Vilmarie Fraguada
Rhea, Joseph
Luoma, Jason B.
Author_xml – sequence: 1
  givenname: Brian
  orcidid: 0000-0002-6211-4586
  surname: Pilecki
  fullname: Pilecki, Brian
– sequence: 2
  givenname: Jason B.
  surname: Luoma
  fullname: Luoma, Jason B.
– sequence: 3
  givenname: Geoff J.
  surname: Bathje
  fullname: Bathje, Geoff J.
– sequence: 4
  givenname: Joseph
  surname: Rhea
  fullname: Rhea, Joseph
– sequence: 5
  givenname: Vilmarie Fraguada
  surname: Narloch
  fullname: Narloch, Vilmarie Fraguada
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33827588$$D View this record in MEDLINE/PubMed
BookMark eNp9kk1v1DAQhiNURD_gD3BAkbhwSfE4_rwgVVWBShVc4Gx5ncnGq6y92Eml_fd4d1voVgj54LH9zDu25z2vTkIMWFVvgVwCKPExA9WcNYRCQwhTuoEX1RkwKRvJQZ48iU-r85xXhBS-Va-q07ZVVHKlzqpvN9PgnR1rG7p6xGWJfM4z5tqHepO3bsAOR-_qwaZ1nbCb3eRj2OM-TLhMdr-eBkx2s31dveztmPHNw3xR_fx88-P6a3P3_cvt9dVd47hop0YwoFb2iJIpEE7wTlKnVStAO8tQIKCw4Cx2jiBq20KrpWYL6ogDZXl7Ud0edLtoV2aT_NqmrYnWm_1GTEtj0-TdiIYpxWGhlKSgGe9KyKlyUnNN6KK1omh9Omht5sW6VMQwJTseiR6fBD-YZbw3ilAlhS4CHx4EUvxVvm4ya58djqMNGOdsKAdCeekQK-j7Z-gqzimUr9pRTLWSCfhLlXag8aGPpa7biZorUc6lJKAKdfkPqowO194Vq_S-7B8lvHv60D8vfHRDAdQBcCnmnLA3zk_7_hZlPxogZmc8czCeKcYze-OZ3ZXps9RH9f8k_Qb1g9gl
CitedBy_id crossref_primary_10_3390_ejihpe14030038
crossref_primary_10_1177_02698811241249698
crossref_primary_10_1038_s41598_023_41145_x
crossref_primary_10_1038_s41598_024_69688_7
crossref_primary_10_3390_psychoactives3030022
crossref_primary_10_1002_cpp_2880
crossref_primary_10_7759_cureus_45169
crossref_primary_10_1016_j_socscimed_2024_117134
crossref_primary_10_1080_02791072_2022_2108356
crossref_primary_10_3389_fpsyg_2023_1054692
crossref_primary_10_1016_j_drugpo_2024_104514
crossref_primary_10_1080_1177083X_2025_2467035
crossref_primary_10_1016_j_newideapsych_2022_100967
crossref_primary_10_1080_13803395_2024_2363343
crossref_primary_10_1093_nc_niad017
crossref_primary_10_1177_02698811241257839
crossref_primary_10_1177_07067437221111371
crossref_primary_10_1186_s12954_022_00662_0
crossref_primary_10_1615_IntJMedMushrooms_2024056373
crossref_primary_10_1016_j_drugpo_2021_103429
crossref_primary_10_1017_S1092852924002268
crossref_primary_10_1007_s13670_023_00383_7
crossref_primary_10_1080_02791072_2023_2276230
crossref_primary_10_1089_psymed_2024_0019
crossref_primary_10_1016_j_pnpbp_2024_111177
crossref_primary_10_1038_s41386_023_01710_4
crossref_primary_10_1176_appi_ps_20220525
crossref_primary_10_1558_ijsnr_20152
crossref_primary_10_3390_ph15050640
crossref_primary_10_1177_02698811231179801
crossref_primary_10_1089_psymed_2023_0004
crossref_primary_10_1186_s40337_024_01185_8
crossref_primary_10_1080_15401383_2023_2237868
crossref_primary_10_3389_fpsyg_2022_863247
crossref_primary_10_1038_s44220_024_00302_5
crossref_primary_10_1177_02698811231158245
crossref_primary_10_1111_anoc_12226
crossref_primary_10_1016_j_neuropharm_2024_110280
crossref_primary_10_1017_S1478951524001494
crossref_primary_10_1089_psymed_2024_0027
crossref_primary_10_59324_ejahss_2024_1_3__10
crossref_primary_10_61373_pp024r_0040
crossref_primary_10_1002_fhu2_70009
crossref_primary_10_1007_s00204_024_03765_8
crossref_primary_10_1002_fhu2_70004
crossref_primary_10_1007_s10615_025_00988_9
crossref_primary_10_1016_j_neuropharm_2022_109214
crossref_primary_10_3389_fpsyt_2021_737738
crossref_primary_10_3390_philosophies8050076
crossref_primary_10_1556_2054_2022_00211
crossref_primary_10_1016_j_jad_2023_03_083
crossref_primary_10_1007_s12152_023_09536_z
crossref_primary_10_1093_tbm_ibae053
crossref_primary_10_1055_a_2282_4731
crossref_primary_10_1007_s12144_024_06272_2
crossref_primary_10_1080_14786419_2022_2103697
crossref_primary_10_1186_s40337_024_01125_6
crossref_primary_10_1089_psymed_2023_0074
crossref_primary_10_3389_fpsyg_2023_1119115
crossref_primary_10_1080_02791072_2022_2129885
crossref_primary_10_3174_ajnr_A8118
crossref_primary_10_1177_00221678221085800
crossref_primary_10_1556_2054_2022_00200
crossref_primary_10_1556_2054_2022_00207
crossref_primary_10_3390_cancers16091702
Cites_doi 10.1177/0022167816670996
10.1016/S0140-6736(10)61462-6
10.1046/j.1360-0443.2001.96811397.x
10.1002/jclp.20669
10.1177/0269881108093587
10.1080/10508422.2013.860030
10.1016/j.jcbs.2019.12.004
10.1093/jtm/tax068
10.1177/009318531103900204
10.1556/2054.2019.016
10.2190/W6L6-G171-M4FT-TWAP
10.15288/jsad.2015.76.749
10.1556/2054.2019.015
10.3389/fphar.2018.00733
10.1186/1471-2458-14-297
10.1016/S0140-6736(02)08701-9
10.1007/978-1-4899-1934-2_24
10.1556/2054.2019.003
10.1186/2211-1522-2-1
10.1556/2054.2019.031
10.1186/s12888-018-1824-6
10.1177/0269881118806297
10.1177/0269881112439253
10.1016/j.drugpo.2014.11.007
10.1080/00275514.1971.12019194
10.1177/0269881116675513
10.1016/j.pharmthera.2018.11.010
10.1038/nrn3530
10.1080/16066359.2016.1242722
10.7326/0003-4819-148-10-200805200-00215
10.1093/hsw/28.2.117
10.1016/j.drugpo.2018.11.001
10.1007/s00213-018-5010-9
10.1080/02791072.1998.10399712
10.1080/02791072.2014.973125
10.12688/f1000research.2-98.v1
10.1556/2054.2020.00124
10.1007/s00213-017-4771-x
10.1126/science.163.3864.245
10.1124/pr.115.011478
10.4135/9781452220680.n1
10.3310/hta11090
10.1177/0022167816673493
10.3109/00952990.2016.1170135
10.1080/02791072.2020.1769878
10.1071/NB10007
10.1007/BF02862854
10.1556/2054.2018.001
10.1080/1751696X.2014.993244
ContentType Journal Article
Copyright COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021
Copyright_xml – notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021
DBID AAYXX
CITATION
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
ATCPS
AZQEC
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
M0S
M1P
PATMY
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PYCSY
7X8
5PM
DOA
DOI 10.1186/s12954-021-00489-1
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest One Sustainability
ProQuest Central UK/Ireland
Agricultural & Environmental Science Collection
ProQuest Central Essentials
ProQuest Central Database Suite (ProQuest)
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Collection (ProQuest)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Environmental Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Environmental Science Collection
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ: Directory of Open Access Journal (DOAJ)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Agricultural & Environmental Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Environmental Science Collection
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Environmental Science Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

CrossRef


MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journal Collection
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Social Welfare & Social Work
EISSN 1477-7517
EndPage 14
ExternalDocumentID oai_doaj_org_article_48851b88721945d1b8528c795902b3a6
PMC8028769
A661377018
33827588
10_1186_s12954_021_00489_1
Genre Letter
Correspondence
GeographicLocations United States
United States--US
GeographicLocations_xml – name: United States
– name: United States--US
GrantInformation_xml – fundername: ;
GroupedDBID ---
0R~
29I
2WC
2XV
53G
5GY
5VS
7X7
7XC
88E
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABIVO
ABUWG
ACGFO
ACGFS
ACHQT
ACIHN
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
ATCPS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IHR
INH
INR
IPY
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PATMY
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PYCSY
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
NPM
PMFND
3V.
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c563t-6412a7fee74816c65d72c983619ca4e6e1e6a1caedc0ee9a3139794b2c0c18a53
IEDL.DBID 7X7
ISSN 1477-7517
IngestDate Wed Aug 27 00:54:58 EDT 2025
Thu Aug 21 18:36:51 EDT 2025
Fri Jul 11 04:14:34 EDT 2025
Fri Jul 25 22:27:33 EDT 2025
Tue Jun 17 21:08:15 EDT 2025
Tue Jun 10 20:28:01 EDT 2025
Thu Apr 03 07:03:21 EDT 2025
Thu Apr 24 23:07:17 EDT 2025
Tue Jul 01 00:46:58 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Harm reduction
Psychedelic integration
Psychedelic-assisted therapy
Psychedelics
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c563t-6412a7fee74816c65d72c983619ca4e6e1e6a1caedc0ee9a3139794b2c0c18a53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Correspondence-1
ORCID 0000-0002-6211-4586
OpenAccessLink https://www.proquest.com/docview/2514837461?pq-origsite=%requestingapplication%
PMID 33827588
PQID 2514837461
PQPubID 105462
PageCount 14
ParticipantIDs doaj_primary_oai_doaj_org_article_48851b88721945d1b8528c795902b3a6
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8028769
proquest_miscellaneous_2510250484
proquest_journals_2514837461
gale_infotracmisc_A661377018
gale_infotracacademiconefile_A661377018
pubmed_primary_33827588
crossref_citationtrail_10_1186_s12954_021_00489_1
crossref_primary_10_1186_s12954_021_00489_1
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-04-07
PublicationDateYYYYMMDD 2021-04-07
PublicationDate_xml – month: 04
  year: 2021
  text: 2021-04-07
  day: 07
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Harm reduction journal
PublicationTitleAlternate Harm Reduct J
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References 489_CR66
DJ Nutt (489_CR49) 2010; 376
JH Tanne (489_CR14) 2014; 328
AT Shulgin (489_CR15) 1978
ECHM Haijen (489_CR27) 2018; 2018
A Tatarsky (489_CR39) 2002
489_CR60
RR Griffiths (489_CR20) 2016; 30
DE Logan (489_CR41) 2010; 66
JR George (489_CR62) 2020; 4
489_CR64
MN Steers (489_CR56) 2015; 76
M Pollan (489_CR1) 2018
P Denning (489_CR47) 2004
A Wodak (489_CR42) 2010; 21
GT Flaherty (489_CR5) 2017; 24
E Fotiou (489_CR65) 2020; 4
RJ Vallerand (489_CR53) 2012; 2
Z Postranecka (489_CR13) 2019; 3
DP Wilson (489_CR43) 2015; 26
RE Schultes (489_CR7) 1969; 163
MW Johnson (489_CR25) 2008; 22
JC Callaway (489_CR50) 1998; 30
ER Weitzman (489_CR45) 2004; 34
489_CR17
MP Bogenschutz (489_CR21) 2017; 57
MW Johnson (489_CR3) 2019; 197
AK Davis (489_CR55) 2017; 25
JB Luoma (489_CR2) 2020; 52
J Brocato (489_CR36) 2003; 28
A Hofmann (489_CR11) 2013
MW Johnson (489_CR22) 2016; 43
AM Haeny (489_CR58) 2014; 24
TS Krebs (489_CR23) 2012; 26
AK Davis (489_CR54) 2015; 47
AL Danforth (489_CR24) 2018; 235
P Denning (489_CR37) 2011
E Ekman Schenberg (489_CR69) 2018; 9
TG Gutheil (489_CR59) 2011; 39
B Lowy (489_CR8) 1971; 63
MT Williams (489_CR68) 2020; 4
DE Nichols (489_CR57) 2016; 68
K Weingardt (489_CR40) 1998
M Doe-Simkins (489_CR46) 2014; 14
FC Measham (489_CR52) 2019; 67
E Guerra-Doce (489_CR6) 2015; 8
AR Winstock (489_CR51) 2001; 96
WA Richards (489_CR28) 2017; 57
G Ona (489_CR32) 2018; 2
EE Schenberg (489_CR26) 2018; 9
N Heather (489_CR35) 1993
D Peluso (489_CR61) 2020; 4
H Liu (489_CR48) 2008; 148
SC Carlin (489_CR70) 2019; 29
TS Krebs (489_CR4) 2013; 2
L Grinspoon (489_CR12) 1979
489_CR33
489_CR34
489_CR38
489_CR30
M Connock (489_CR44) 2007; 11
JG Bruhn (489_CR9) 2002; 359
TI Michaels (489_CR63) 2018; 18
489_CR29
DJ Nutt (489_CR16) 2013; 14
GM Ot'alora (489_CR18) 2018; 32
R Watts (489_CR31) 2020; 15
MT Williams (489_CR67) 2020; 4
JG Bruhn (489_CR10) 1973; 28
RL Carhart-Harris (489_CR19) 2018; 235
References_xml – ident: 489_CR33
– volume: 57
  start-page: 323
  year: 2017
  ident: 489_CR28
  publication-title: J Humanist Psychol
  doi: 10.1177/0022167816670996
– volume: 376
  start-page: 1558
  year: 2010
  ident: 489_CR49
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)61462-6
– volume: 96
  start-page: 1139
  year: 2001
  ident: 489_CR51
  publication-title: Addiction
  doi: 10.1046/j.1360-0443.2001.96811397.x
– ident: 489_CR66
– volume: 66
  start-page: 201
  year: 2010
  ident: 489_CR41
  publication-title: J Clin Psychol
  doi: 10.1002/jclp.20669
– volume-title: How to change your mind: what the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence
  year: 2018
  ident: 489_CR1
– volume: 22
  start-page: 603
  issue: 6
  year: 2008
  ident: 489_CR25
  publication-title: J Psychopharmacol
  doi: 10.1177/0269881108093587
– volume: 24
  start-page: 265
  year: 2014
  ident: 489_CR58
  publication-title: Ethics Behav
  doi: 10.1080/10508422.2013.860030
– volume: 15
  start-page: 92
  year: 2020
  ident: 489_CR31
  publication-title: J Context Behav Sci
  doi: 10.1016/j.jcbs.2019.12.004
– volume: 24
  start-page: 1
  issue: 6
  year: 2017
  ident: 489_CR5
  publication-title: J Travel Med
  doi: 10.1093/jtm/tax068
– volume: 39
  start-page: 237
  year: 2011
  ident: 489_CR59
  publication-title: J Psychiatry Law
  doi: 10.1177/009318531103900204
– volume: 4
  start-page: 40
  year: 2020
  ident: 489_CR67
  publication-title: J Psychedelic Stud
  doi: 10.1556/2054.2019.016
– volume: 34
  start-page: 247
  year: 2004
  ident: 489_CR45
  publication-title: J Drug Educ
  doi: 10.2190/W6L6-G171-M4FT-TWAP
– volume: 76
  start-page: 749
  year: 2015
  ident: 489_CR56
  publication-title: J Stud Alcohol Drugs
  doi: 10.15288/jsad.2015.76.749
– volume: 4
  start-page: 4
  year: 2020
  ident: 489_CR62
  publication-title: J Psychedelic Stud
  doi: 10.1556/2054.2019.015
– volume: 9
  start-page: 733
  year: 2018
  ident: 489_CR69
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2018.00733
– volume: 14
  start-page: 297
  issue: 1
  year: 2014
  ident: 489_CR46
  publication-title: BMC Public Health
  doi: 10.1186/1471-2458-14-297
– volume: 359
  start-page: 1866
  issue: 9320
  year: 2002
  ident: 489_CR9
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)08701-9
– volume: 29
  start-page: 10
  issue: 1
  year: 2019
  ident: 489_CR70
  publication-title: MAPS Bull Spring
– start-page: 337
  volume-title: Treating addictive behaviors
  year: 1998
  ident: 489_CR40
  doi: 10.1007/978-1-4899-1934-2_24
– volume: 3
  start-page: 19
  issue: 1
  year: 2019
  ident: 489_CR13
  publication-title: J Psychedelic Stud
  doi: 10.1556/2054.2019.003
– volume: 2
  start-page: 1
  year: 2012
  ident: 489_CR53
  publication-title: Psychol Well-Being
  doi: 10.1186/2211-1522-2-1
– volume: 4
  start-page: 16
  year: 2020
  ident: 489_CR65
  publication-title: J Psychedelic Stud
  doi: 10.1556/2054.2019.031
– volume: 18
  start-page: 1
  year: 2018
  ident: 489_CR63
  publication-title: BMC Psychiatry
  doi: 10.1186/s12888-018-1824-6
– volume-title: Psychedelic drugs reconsidered
  year: 1979
  ident: 489_CR12
– volume: 32
  start-page: 1295
  issue: 12
  year: 2018
  ident: 489_CR18
  publication-title: J Psychopharmacol
  doi: 10.1177/0269881118806297
– volume: 26
  start-page: 994
  issue: 7
  year: 2012
  ident: 489_CR23
  publication-title: J Psychopharmacol
  doi: 10.1177/0269881112439253
– volume: 26
  start-page: S5
  year: 2015
  ident: 489_CR43
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2014.11.007
– volume: 63
  start-page: 983
  year: 1971
  ident: 489_CR8
  publication-title: Mycologia
  doi: 10.1080/00275514.1971.12019194
– ident: 489_CR17
– volume: 30
  start-page: 1181
  issue: 12
  year: 2016
  ident: 489_CR20
  publication-title: J Psychopharmacol
  doi: 10.1177/0269881116675513
– ident: 489_CR30
– volume: 197
  start-page: 83
  year: 2019
  ident: 489_CR3
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2018.11.010
– ident: 489_CR38
– volume: 14
  start-page: 577
  year: 2013
  ident: 489_CR16
  publication-title: Nat Rev Neurosci
  doi: 10.1038/nrn3530
– ident: 489_CR60
– volume-title: Practicing harm reduction psychotherapy: an alternative approach to addictions
  year: 2004
  ident: 489_CR47
– volume: 25
  start-page: 188
  issue: 3
  year: 2017
  ident: 489_CR55
  publication-title: Addict Res Theory
  doi: 10.1080/16066359.2016.1242722
– volume-title: Psychoactive drugs and harm reduction: from faith to science
  year: 1993
  ident: 489_CR35
– volume: 148
  start-page: 747
  issue: 10
  year: 2008
  ident: 489_CR48
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-148-10-200805200-00215
– ident: 489_CR29
– volume: 28
  start-page: 117
  year: 2003
  ident: 489_CR36
  publication-title: Health Soc Work
  doi: 10.1093/hsw/28.2.117
– volume: 67
  start-page: 102
  year: 2019
  ident: 489_CR52
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2018.11.001
– volume: 235
  start-page: 3137
  issue: 11
  year: 2018
  ident: 489_CR24
  publication-title: Psychopharmacology
  doi: 10.1007/s00213-018-5010-9
– ident: 489_CR64
– volume: 328
  start-page: 713
  issue: 7441
  year: 2014
  ident: 489_CR14
  publication-title: BMJ
– volume-title: Practicing harm reduction psychotherapy: an alternative approach to addictions
  year: 2011
  ident: 489_CR37
– volume: 30
  start-page: 367
  year: 1998
  ident: 489_CR50
  publication-title: J Psychoact Drugs
  doi: 10.1080/02791072.1998.10399712
– volume: 47
  start-page: 24
  year: 2015
  ident: 489_CR54
  publication-title: J Psychoact Drugs
  doi: 10.1080/02791072.2014.973125
– volume: 2
  start-page: 98
  year: 2013
  ident: 489_CR4
  publication-title: F1000Research
  doi: 10.12688/f1000research.2-98.v1
– volume: 4
  start-page: 24
  year: 2020
  ident: 489_CR61
  publication-title: J Psychedelic Stud
  doi: 10.1556/2054.2020.00124
– volume: 235
  start-page: 399
  issue: 2
  year: 2018
  ident: 489_CR19
  publication-title: Psychopharmacology
  doi: 10.1007/s00213-017-4771-x
– volume: 163
  start-page: 245
  issue: 3864
  year: 1969
  ident: 489_CR7
  publication-title: Science
  doi: 10.1126/science.163.3864.245
– volume: 4
  start-page: 1
  issue: 245
  year: 2020
  ident: 489_CR68
  publication-title: J Psychedelic Stud
– volume-title: The psychopharmacology of hallucinogens
  year: 1978
  ident: 489_CR15
– volume: 68
  start-page: 264
  year: 2016
  ident: 489_CR57
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.115.011478
– volume-title: LSD: my problem child
  year: 2013
  ident: 489_CR11
– volume: 9
  start-page: 1
  year: 2018
  ident: 489_CR26
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2018.00733
– volume: 2018
  start-page: 1
  issue: 9
  year: 2018
  ident: 489_CR27
  publication-title: Front Pharmacol
– ident: 489_CR34
  doi: 10.4135/9781452220680.n1
– volume: 11
  start-page: 1
  year: 2007
  ident: 489_CR44
  publication-title: Health Technol Assess
  doi: 10.3310/hta11090
– volume: 57
  start-page: 389
  year: 2017
  ident: 489_CR21
  publication-title: J Humanist Psychol
  doi: 10.1177/0022167816673493
– volume: 43
  start-page: 55
  issue: 1
  year: 2016
  ident: 489_CR22
  publication-title: J Drug Alcohol Abuse
  doi: 10.3109/00952990.2016.1170135
– volume-title: Harm reduction psychotherapy
  year: 2002
  ident: 489_CR39
– volume: 52
  start-page: 289
  issue: 4
  year: 2020
  ident: 489_CR2
  publication-title: J Psychoact Drugs
  doi: 10.1080/02791072.2020.1769878
– volume: 21
  start-page: 69
  year: 2010
  ident: 489_CR42
  publication-title: NSW Public Health Bulletin
  doi: 10.1071/NB10007
– volume: 28
  start-page: 353
  year: 1973
  ident: 489_CR10
  publication-title: Econ Bot
  doi: 10.1007/BF02862854
– volume: 2
  start-page: 53
  year: 2018
  ident: 489_CR32
  publication-title: J Psychedelic Stud
  doi: 10.1556/2054.2018.001
– volume: 8
  start-page: 91
  issue: 1
  year: 2015
  ident: 489_CR6
  publication-title: Time Mind J Archaeol Conscious Cult
  doi: 10.1080/1751696X.2014.993244
SSID ssj0029538
Score 2.5055578
Snippet Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated...
Abstract Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 40
SubjectTerms Clients
Clinical trials
Ecstasy
Ethical aspects
Ethics
Hallucinogenic drugs
Harm reduction
Health problems
Laws, regulations and rules
Legal issues
LSD
Lysergic acid diethylamide
Marginalized groups
Medical ethics
Mental disorders
Mental health
Mental health care
Methods
Opinion
Post traumatic stress disorder
Psychedelic drugs
Psychedelic integration
Psychedelic-assisted therapy
Psychedelics
Psychotherapy
Reduction
Risk reduction
Therapists
Therapy
SummonAdditionalLinks – databaseName: DOAJ: Directory of Open Access Journal (DOAJ)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT70gaHkEtshICA4oahw7fhwLoqqQ6ImK3izHnogVqyza3R767zvjJKuNkODCLY4nie2Zib-Rx58Ze1dZcLIJGpGbSqUKqSoRHMVS1ZA6rWxUgVZ0v13rqxv19ba5PTjqi3LCBnrgYeDO0cAa0aIroGupJuFlU9tIJ2RXdStDJtvGOW8KpsZQy6EfT1tkrD7fClrOKikdgUzWlWI2DWW2_j__yQeT0jxh8mAGunzCHo_QkV8MTX7KHkF_whbD_lr-A1Zd2AB_z6cb682vU3ad89mxGPrEV4Cf5nmkt3zZ85zpDAlWy8iJwZpviMeVNJXFJyYJKg_btO6fsZvLL98_X5XjEQplbLTclVqJOpgOwCgrdNRNMnV0VmLYFIMCDQJ0EDFg1yoAFyQBQqfaOlZR2NDI5-yoX_fwkvGUDCCY6qSjlTnoQuuia1JrwaQg21QwMY2ojyO_OB1zsfI5zrDaD1rwqAWfteBFwT7un_k9sGv8VfoTKWovSczY-Qbaix_txf_LXgr2gdTsyX-xeTGM2xCwk8SE5S8QsEhjKmELtphJot_FefVkKH70-61HtEgU_UpjY9_uq-lJymXrYX2XZTJxnFUFezHY1b5LUtoaIzh8uZlZ3KzP85p--TOzgltEika7V_9jkF6z4zo7C_qMWbCj3eYOzhB87do32c8eAPXmKBA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Ni9UwEA_LevEiflt9SgTRg1TbJk3Sg8gqLouwe_Lh3kKaTPVh6dO-t-D-986kH2xx2VvTTNokM5PMkMlvGHuVGahE6RRabjKk0oUsRePIp7KA0ChpvHR0ont6pk7W8ut5eX7ApnRH4wTurnXtKJ_Uum_f_f1z-REV_kNUeKPe73I6rEop2IAEskrRG7qFO5MmRT2V86kCUgkzXZy5tt1ic4oY_v-v1Fe2qmUY5ZV96fguuzMalPxokIB77AC6-2w13Lrl36FtXA_8NZ9ebPtfD9hZjHLHousCbwF_zeP87_im4zH-GQK0G88J15r3hO5K_IvkE74ElYfLW5cP2fr4y7fPJ-mYWCH1pRL7VMm8cLoB0NLkyqsy6MJXRqAz5Z0EBTkol3uHQ8sAKifITKxkXfjM58aV4hE77LYdPGE8BA1oYjWiovM6aFxd-aoMtQEdnKhDwvJpRq0fUccp-UVro_dhlB24YJELNnLB5gl7O7f5PWBu3Ej9iRg1UxJednyx7X_YUf0sLlNlXuOCigu0LAM-loXxlGc9K2rhVMLeEJstyRl2z7vxcgIOkvCx7BGaMULrLDcJWy0oURv9snoSFDsJs0UbkoD7pcLOvpyrqSVFuHWwvYg0EU7OyIQ9HuRqHpIQpkC_Dj-uFxK3GPOyptv8jFjhBu1HraqnN3frGbtdRDVAbdArdrjvL-A5Glv7-kXUoH-24CS8
  priority: 102
  providerName: Scholars Portal
Title Ethical and legal issues in psychedelic harm reduction and integration therapy
URI https://www.ncbi.nlm.nih.gov/pubmed/33827588
https://www.proquest.com/docview/2514837461
https://www.proquest.com/docview/2510250484
https://pubmed.ncbi.nlm.nih.gov/PMC8028769
https://doaj.org/article/48851b88721945d1b8528c795902b3a6
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagvXBBvAldVkZCcEBR49ixnRPaolbVSl0hoGJvlmN7YcUqKdntof-eGSfZNkLqJS9PHs48PLbH3xDyPtOh5IWV4LkJnwrrsxScI5eKPPiVFNoJizO6Fwt5finmy2LZD7ht-7DKwSZGQ-0bh2Pkx9AOI_i5kOzz1d8Us0bh7GqfQuMhOUToMgzpUsvbDlcJ2jwslNHyeMtwUivFoAQU3DJlo8YoYvb_b5nvNE3jsMk77dDZE_K4dyDprOP4U_Ig1M_IpFtlS3-Gzcq2gX6gw4Wm_fOcLGJUO5za2tNNgFfT-L-3dF3TGO8cfNisHUUca9oimivyK5IPeBJ43i3WunlBLs9Of3w5T_tECqkrJN-lUrDcqlUISmgmnSy8yl2pOXSenBVBBhakZc5C1bIQSsvRLSxFlbvMMW0L_pIc1E0dXhPqvQrgUq14ifNzYWWr0pWFr3RQ3vLKJ4QNf9S4HmUck11sTOxtaGk6LhjggolcMCwhn_b3XHUYG_dSnyCj9pSIjx0vNO0v06ubAbNUsAoMKBhkUXg4LHLtMK96llfcyoR8RDYb1GL4PGf7xQhQScTDMjNwW7hSGdMJmYwoQfvcuHgQFNNr_9bcympC3u2L8U6MaKtDcx1pInycFgl51cnVvkqc6xz6cfBwNZK4UZ3HJfX6d8QG1-AvKlm-uf-zjsijPKoBaIOakINdex3egnO1q6ZRg6bkcDabf5_D_uR08fXbNA5VwPZC6H-K2yaI
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Nb9MwFLem7gAXxDeBAkbi44CixYnjOAeENtjUsa1CaBO7Gcd-hYoqHW0ntH-Kv5H3nKQsQtpttyR-SeO87_r59xh7mWgos9wqjNykj6X1SYzBkYtlCn6ipHbS0oru0ViNTuSn0_x0g_3p9sJQWWVnE4Oh9nNH_5FvoR8m8HOpxPuzXzF1jaLV1a6FRiMWB3DxG1O25bv9j8jfV2m6t3v8YRS3XQVil6tsFSspUltMAAqphXIq90XqSp1hJuGsBAUClBXOgncJQGkzipFKWaUucUJb6hKBJn9TZpjKDNjmzu7485d1ilei_ei25mi1tRS0jBZTGQSpShmLnvsLXQL-9wWXnGG_UPOS59u7zW61ISvfbmTsDtuA-i4bNvt6-VeYTewC-GveXZgvft5j41BHj6e29nwG-NM8cHjJpzUPFdbgYTZ1nJCz-YLwY0lCAnmHYEHnzfawi_vs5Fo-8gM2qOc1PGLc-wIwiJtkJa0IwsRWpStzX2kovM0qHzHRfVHjWlxzaq8xMyG_0co0XDDIBRO4YETE3q7vOWtQPa6k3iFGrSkJkTtcmC--m1bBDRrCXFRostEFyNzjYZ5qR53ck7TKrIrYG2KzIbuBr-dsu_0BJ0kIXGYbA6WsKBKhIzbsUaK-u_5wJyimtTdL8087IvZiPUx3Ug1dDfPzQBMA67SM2MNGrtZTyjKdYuaIDy96Etebc3-knv4IaOQaI9RClY-vfq3n7Mbo-OjQHO6PD56wm2lQCdSMYsgGq8U5PMXQblU9a_WJs2_XrcJ_AX_eYAI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ethical+and+legal+issues+in+psychedelic+harm+reduction+and+integration+therapy&rft.jtitle=Harm+reduction+journal&rft.au=Pilecki%2C+Brian&rft.au=Luoma%2C+Jason+B&rft.au=Bathje%2C+Geoff+J&rft.au=Rhea%2C+Joseph&rft.date=2021-04-07&rft.pub=BioMed+Central&rft.eissn=1477-7517&rft.volume=18&rft.spage=1&rft_id=info:doi/10.1186%2Fs12954-021-00489-1
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-7517&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-7517&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-7517&client=summon